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We appreciate the interest of Ieven and colleagues in our work. They discussed the possible shortcomings of the microimmunofluorescence (MIF) test technique that we used in our study, but as they stated correctly, the MIF test is still considered the gold standard in Chlamydia pneumoniae (Cp) serology. 1 We used the most widely taken MIF assay to determine Cp seropositivity, 2 which has already been used in several other studies. In the study of Peeling et al, 3 the overall agreement with the reference standard titers was 80% and the range 60% to 90%. Based on these findings Peeling et al 3 stated that the MIF test, if performed properly, is sensitive and specific for the serodiagnosis of Cp infections.
In contrast to the cited study by Hoymans et al, 4 we used clearly higher cutoff titers for Cp positivity (IgG Ն1:64 or IgA Ն1:16) to reduce the possibility of including "false" positive patients. Using this definition, we identified only 46% Cppositive subjects in our group of patients over age 55 with cerebrovascular diseases. There is growing evidence that the combined use of IgA titers and the detection of Cp DNA in peripheral blood mononuclear cells-as a marker for endovascular Cp infection-is a powerful approach to determining chronic infection. 1, 5 Ieven et al pointed out that uncertainties of results with polymerase chain reaction (PCR) analysis for Cp from histopathological examinations occur, mainly as a result of operator dependency and the fact that the detection rate may vary markedly with the primer used. 5 However, Cp has been demonstrated not only by PCR analysis but also by culturing of viable Cp from carotid plaque material, detection of chlamydial HSP 60 in all carotid plaque specimens positive for Cp specific antigen, 6 and retrieval of Cp-reactive T lymphocytes from human atherosclerotic plaques. 1 These results imply that Cp is a key microbial organ that causes atheroma developments in the carotid artery. Additionally, recent advances in PCR techniques using real-time PCR may allow an accurate, high-throughput detection of Cp. 7 We agree with Ieven et al that macrolides have antiinflammatory, antioxidant, or antithrombotic actions. 5 However, using trial protocols that include Cp-negative control groups, it will be possible to differentiate the antibacterial efficacy from other macrolide effects. Additionally, treating Cp infection in carotid artery plaque with roxithromycin, this regime resulted in Cp eradication of 69% versus only 25% for nontreated patients and thus demonstrates the role of Cp for atherosclerosis. 5 
